Drug Trial Radar · NCT02935634
A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer
Last checked: Nov 19, 2026Latest source record: Jun 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
190
Actual
Start
Nov 29, 2016
Primary completion
May 11, 2022
Study completion May 11, 2022
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Clovis Oncology, Inc.
- First posted
- Oct 17, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the preliminary efficacy, safety, and tolerability of Nivolumab in combination with Ipilimumab or other treatment therapies in participants with advanced gastric cancer.
Conditions
- Advanced Gastric Cancer
Interventions
NivolumabBiological
Specified dose on specified days
IpilimumabBiological
Specified dose on specified days
RelatlimabBiological
Specified dose on specified days
BMS-986205Biological
Specified dose on specified days
RucaparibDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) by InvestigatorTime frame: From first dose of study treatment until progression or subsequent anticancer therapy, whichever occurs first (up to approximately 65 months)
- Median Duration of Response (DOR)Time frame: From first dose to date of first documented tumor progression or death due to any cause, whichever occurred first (up to approximately 65 months)
- Kaplan-Meier Analysis of Progression Free Survival Rate (PFSR) at 24 WeeksTime frame: 24 weeks after first dose
Locations
35 sites in 9 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Phoenix, Arizona
Local Institution - 0020
Duarte, California
University Of Colorado
Aurora, Colorado
Local Institution - 0032
New Haven, Connecticut
Local Institution - 0036
Washington D.C., District of Columbia
UF Health Medical Oncology - Davis Cancer Pavilion
Gainesville, Florida
Local Institution - 0038
Jacksonville, Florida
Local Institution - 0006
Baltimore, Maryland
Local Institution - 0017
Rochester, Minnesota
Local Institution - 0003
St Louis, Missouri
Local Institution - 0001
Hackensack, New Jersey
Local Institution - 0007
New York, New York
Local Institution - 0002
Portland, Oregon
Local Institution - 0005
Philadelphia, Pennsylvania
UPMC
Pittsburgh, Pennsylvania
Local Institution - 0004
Seattle, Washington
Local Institution
Randwick, Australia
Local Institution - 0035
Westmead, New South Wales, Australia
Local Institution - 0033
Heidelberg, Victoria, Australia
Local Institution
Edmonton, Alberta, Canada
Local Institution
Vancouver, British Columbia, Canada
Local Institution
Ottawa, Ontario, Canada
Local Institution - 0025
Toronto, Ontario, Canada
Local Institution - 0021
Toronto, Ontario, Canada
Local Institution - 0039
Heidelberg, Germany
Local Institution - 0043
Leipzig, Germany
Local Institution
Ramat Gan, Israel
Local Institution
Tel Aviv, Israel
IRCCS Istituto Nazionale Tumori Milano
Milan, Italy
Local Institution - 0014
Milan, Lombardy, Italy
Local Institution
Amsterdam, Netherlands
Local Institution
Utrecht, Netherlands
Local Institution - 0050
Singapore, Singapore
Local Institution - 0042
Zurich, Switzerland
Local Institution - 0041
Chur, Graubünden (de), Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.